NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ovelle Bio Corp.

Ovelle Bio Corp.

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://ovelle.bio/

Last Round

Seed Round

Jun 10, 2026

Total Funding Raised

$667,000

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Ovelle Bio Corp. is a biotechnology company developing in vitro gametogenesis (IVG), a revolutionary approach to create eggs from somatic cells to provide a more effective and less invasive alternative to traditional IVF.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical AI

Business Model

B2B2C

Customer Profile

Services & Consulting, Usage-Based SaaS

AI Layer

Application

Keywords

in vitro gametogenesisIVGlab-grown eggsin vitro oogenesisinfertility treatmentIVF alternativefertility technologysynthetic ovaries3D ovarian organoidsinduced pluripotent stem cellsiPSCseggs from skin cellsreproductive technologyAI for biologycomputational biologyfertility preservation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ovelle Bio Corp. Comparables

Compare Ovelle Bio Corp. with similar companies based on industry and business-model similarity.

Ovelle Bio Corp. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ivy Natal
92%
Vitra Labs
88%
Dioseve Inc.
85%

Ovelle Bio Corp. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundJun 10, 2026
GrantSep 1, 2025

Key People

Founding team and executive leadership

Travis Potter

Co-Founder, CEO

Founding Team

Ovelle Bio Corp. Investors

Notable investors and investment history

Ovelle Bio Corp. investors
InvestorRounds
Survival and Flourishing FundGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 10, 2026

    $7M round raised.

  • Jul 19, 2025

    Grew 100% QoQ from 3 to 6 employees.

Ovelle Bio Corp. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ovelle Bio Corp. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ovelle Bio Corp.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range7
Year Founded2024
Last FundingJun 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.